

Jarle Bruun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10650091/publications.pdf>

Version: 2024-02-01

31
papers

1,942
citations

394421

19
h-index

454955

30
g-index

32
all docs

32
docs citations

32
times ranked

3801
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer stemness, intratumoral heterogeneity, and immune response across cancers. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9020-9029.	7.1	372
2	Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. Molecular Cancer, 2017, 16, 116.	19.2	232
3	CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Scientific Reports, 2017, 7, 16618.	3.3	229
4	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research, 2018, 24, 794-806.	7.0	177
5	Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients. Journal of Pathology, 2018, 244, 421-431.	4.5	159
6	Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. International Journal of Cancer, 2012, 131, 570-581.	5.1	100
7	Combination therapies with HSP90 inhibitors against colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 240-247.	7.4	81
8	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. Clinical Cancer Research, 2020, 26, 4107-4119.	7.0	68
9	Prognostic Significance of β -Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series. Frontiers in Oncology, 2014, 4, 118.	2.8	63
10	The Gap Junction Channel Protein Connexin 43 Is Covalently Modified and Regulated by SUMOylation. Journal of Biological Chemistry, 2012, 287, 15851-15861.	3.4	57
11	Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage. British Journal of Cancer, 2019, 121, 474-482.	6.4	41
12	Prognostic, predictive, and pharmacogenomic assessments of CDX^2 refine stratification of colorectal cancer. Molecular Oncology, 2018, 12, 1639-1655.	4.6	40
13	Connexins in colorectal cancer pathogenesis. International Journal of Cancer, 2015, 137, 1-11.	5.1	39
14	Smad ubiquitination regulatory factor-2 controls gap junction intercellular communication by modulating endocytosis and degradation of connexin43. Journal of Cell Science, 2012, 125, 3966-76.	2.0	37
15	Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 3759-3770.	7.0	32
16	Common Fusion Transcripts Identified in Colorectal Cancer Cell Lines by High-Throughput RNA Sequencing. Translational Oncology, 2013, 6, 546-IN5.	3.7	29
17	Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2. Laboratory Investigation, 2020, 100, 120-134.	3.7	26
18	Identification of Novel Fusion Genes in Testicular Germ Cell Tumors. Cancer Research, 2016, 76, 108-116.	0.9	25

#	ARTICLE	IF	CITATIONS
19	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine, 2020, 59, 102923.	6.1	22
20	A novel transcript, <i>VNN1-AB</i> , as a biomarker for colorectal cancer. International Journal of Cancer, 2014, 135, 2077-2084.	5.1	18
21	Exome Sequencing of Bilateral Testicular Germ Cell Tumors Suggests Independent Development Lineages. Neoplasia, 2015, 17, 167-174.	5.3	17
22	A panel of intestinal differentiation markers (CDX2, GPA33, and LI-cadherin) identifies gastric cancer patients with favourable prognosis. Gastric Cancer, 2020, 23, 811-823.	5.3	16
23	Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. Molecular Oncology, 2017, 11, 1156-1171.	4.6	15
24	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open, 2019, 4, e000523.	4.5	11
25	Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. British Journal of Cancer, 2022, 126, 48-56.	6.4	8
26	Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer. Modern Pathology, 2022, 35, 1236-1246.	5.5	8
27	Antibody crossreactivity between the tumour suppressor PHLPP1 and the proto-oncogene β -catenin. EMBO Reports, 2013, 14, 10-11.	4.5	6
28	Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer. ESMO Open, 2020, 5, e001040.	4.5	6
29	The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine, 2021, 13, 142.	8.2	4
30	E-cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. Molecular Oncology, 2022, 16, 2312-2329.	4.6	4
31	Novel drug discovery by pharmacogenomic profiling of 36 colorectal cancer cell lines.. Journal of Clinical Oncology, 2016, 34, 604-604.	1.6	0